Oppenheimer Encouraged by Mannkind's Continued Progress
Jun 18, 2021 16:32:56 GMT -5
alethea, sportsrancho, and 13 more like this
Post by wyattdog on Jun 18, 2021 16:32:56 GMT -5
Oppenheimer Encouraged by Mannkind's Continued Progress on Tyvaso DPI Application for FDA Approval
3:46 PM ET, 06/18/2021 - MT Newswires
03:46 PM EDT, 06/18/2021 (MT Newswires) -- MannKind (MNKD) Oppenheimer analysts said that they expect FDA approval of Tyvaso DPI to be a significant upcoming catalyst for Mannkind (MNKD), which co-developed the product with United Therapeutics (UTHR).
The analysts said they were encouraged by continued progress on Tyvaso DPI, which is a inhaled version of the drug treprostinil for the treatment of pulmonary arterial hypertension. The FDA is expected to decide on whether to approve the product by October.
Oppenheimer analysts noted that the FDA's approval is subject to an inspection of Mannkind's manufacturing facility in Danbury, Conn. The analysts said that the same facility had been inspected by the FDA three years ago, giving them additional confidence in the drug's application.
Price: 4.25, Change: -0.20, Percent Change: -4.39
3:46 PM ET, 06/18/2021 - MT Newswires
03:46 PM EDT, 06/18/2021 (MT Newswires) -- MannKind (MNKD) Oppenheimer analysts said that they expect FDA approval of Tyvaso DPI to be a significant upcoming catalyst for Mannkind (MNKD), which co-developed the product with United Therapeutics (UTHR).
The analysts said they were encouraged by continued progress on Tyvaso DPI, which is a inhaled version of the drug treprostinil for the treatment of pulmonary arterial hypertension. The FDA is expected to decide on whether to approve the product by October.
Oppenheimer analysts noted that the FDA's approval is subject to an inspection of Mannkind's manufacturing facility in Danbury, Conn. The analysts said that the same facility had been inspected by the FDA three years ago, giving them additional confidence in the drug's application.
Price: 4.25, Change: -0.20, Percent Change: -4.39
